. Author manuscript; available in PMC: 2018 Aug 15.

Published in final edited form as: Cancer. 2017 Apr 7;123(16):3050–3060. doi: 10.1002/cncr.30704

Table 1b.

Baseline high risk disease characteristics by study regimen

Characteristics	Type of regimen
Characteristics	IC (n=396)	Epigenetic (n=221)	CPX-351 (n=20)	LDAC-combinations (n=189)	INV group (n=109)
*Age > 70 (%)*	121 (30) [p< 0.001]	101 (46) [p=0.04]	8 (40) [p=0.14]	66 (36) [p< 0.001]	63 (58) [ref]
*Prior therapy for antecedent disorder (%)*	79 (20) [p< 0.001]	35 (16) [p< 0.001]	13 (65) [ref]	63 (34) [p=0.005]	54 (50) [p=0.2]
*Creatinine ≥ 1.3 (%)*	74 (18.6) [ref]	53 (23.9) [p=0.192]	3 (15) [p= 0.686]	21 (11.1) [p=0.023]	13 (11.9) [p=0.09]
*WBC ≥ 50 K/μL (%)*	23 (5.7) [p=0.003]	2 (0.9) [ref]	2 (10) [P = 0.002]	8 (4.2) [p= 0.445]	3 (2.8) [p= 0.19]
*PS = 2 (%)*	79 (19.8) [ref]	34 (15) [P = 0.164]	4 (20) [P = 0.982]	18 (9.5) [p=0.001]	12 (11) [p=0.03]